Erytech Pharma, a clinical-stage biopharmaceutical company, announced the sale of its US manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.
Under the terms of an asset purchase agreement between Erytech and Catalent (the
